The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial
Open accessAbstract
OBJECTIVE: There is uncertainty about the importance of glycemic variability in cardiovascular complications in patients with type 2 diabetes. Using the Veterans Affairs Diabetes Trial (VADT), we investigated the association between variation in fasting glucose and glycated hemoglobin (HbA1c) over time and the incidence of cardiovascular disease (CVD) and assessed whether this is influenced by intensive or standard glycemic control. RESEARCH DESIGN AND METHODS: During the VADT, fasting glucose and HbA1c were measured every 3 months for up to 84 months in 1,791 individuals. Variability measures included coefficient of variation (CV) and average real variability (ARV) for fasting glucose and HbA1c. Overall mean glucose and HbA1c measures as well as their maximum and the most recent measurement were also examined. RESULTS: Variability measures (CV and ARV) of fasting glucose were significantly associated with CVD even after adjusting for other risk factors, including mean fasting glucose. When considering separately groups receiving intensive and standard glycemic control, this relationship was evident in the intensive treatment group but not in the standard group. Additional adjustment for severe hypoglycemic episodes did not alter the relationship between fasting glucose variability and CVD. Interestingly, no HbA1c measures were associated with CVD after adjusting for multiple baseline risk factors. CONCLUSIONS: Our analysis indicates that in the VADT, variability of fasting glucose plays a role in the development of CVD complications beyond the influence of standard fasting glucose measures. The adverse consequences of fasting glucose variability on CVD appear greatest in those receiving intensive glucose control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CV and ARV of FG were significantly associated with CVD: CV glucose: p=0.003, OR 1.162 (1.054–1.281); ARV glucose: p=0.0006, OR 1.168 (1.069–1.275).”
From Glycemic variability and cardiovascular disease in patients with type 2 diabetes (2021) · cites this paper as [51]
In the citing paper
“The results showed a significant association between variability of fasting glucose and cardiovascular disease even after adjusting for different risk factors, including mean fasting glucose.”
From Glycemic variability and cardiovascular disease in patients with type 2 diabetes (2021) · cites this paper as [51]
In the citing paper
“Conversely, the association was not present for HbA1c variability.”
From Glycemic variability and cardiovascular disease in patients with type 2 diabetes (2021) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Self-citationDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–130 of 130
Kim, R., Kang, N., Byun, K., Park, K., Jun, J., & Jeon, B. (2025) · Age and Ageing · doi:10.1093/ageing/afaf220 · Cited by 2
Lee, S., Liu, T., Chung, C. T., Reinhold, J., Vassiliou, V. S., & Tse, G. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00012-7 · Cited by 3
Glucose and HbA1c variability and time in range (TIR)
Prattichizzo, F., & Ceriello, A. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00969-3 · Cited by 1
Trends in Time in Range–Related Publications and Clinical Trials: A Bibliometric Review
Patel, P. M., Abaniel, R. M., Dogra, N., Lo, C. B., Frazzitta, M. A., & Virdi, N. S. (2023) · Diabetes Spectrum · doi:10.2337/ds22-0085 · Cited by 3
Waataja, J. J., Ikramuddin, S., Gal, D., & Billington, C. J. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002713 · Cited by 1
Erbay, İ., Güdül, N. E., Köktürk, U., & Avcı, A. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001466 · Cited by 1
Strollo, F., Satta, E., Romano, C., Alfarone, C., Corte, T. D., Guarino, G., & Gentile, S. (2020) · Diabetes Research - Open Journal · doi:10.17140/droj-6-147 · Cited by 1
Edward, J. A., Josey, K., Bahn, G., Caplan, L., Reusch, J. E. B., Reaven, P. D., Ghosh, D., & Raghavan, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1439428/v1 · Cited by 1
Self-citationBloomgarden, Z. T. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12973
Glukose- und HbA1c-Variabilität sowie Zeit im Zielbereich (TIR)
Prattichizzo, F., & Ceriello, A. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00968-4
Grotta, R. L. (2024) · The Journal of AMD · doi:10.36171/jamd24.27.1.3
Sugimoto, H., Hironaka, K., Yamada, T., Otowa‐Suematsu, N., Hirota, Y., Otake, H., Hirata, K., Sakaguchi, K., Ogawa, W., & Kuroda, S. (2025) · eLife · doi:10.7554/elife.102860.1
Assessment of Gliflozins prescribing pattern in a United Arab Emirates tertiary-level care hospital
Shenouda, W., Thomas, D., Nabi, O., & Zachariah, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1529528
Liu, M., Pei, J., Hu, X., & Wang, X. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328252 · Cited by 1
Nuyujukian, D. S., Zhou, J., Koška, J., & Reaven, P. D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70083
Self-citationNuyujukian, D. S., Zhou, J. J., Koška, J., Li, S. J., Nwabuo, C. C., Bertoni, A. G., Li, G., & Reaven, P. D. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf226
Self-citationChou, Y.-Y., Liu, F.-H., & Lin, C. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02108-7
Edward, J. A., Josey, K., Bahn, G., Caplan, L., Reusch, J. E. B., Reaven, P. D., Ghosh, D., & Raghavan, S. (2022) · Figshare · doi:10.6084/m9.figshare.19669978
Self-citationYang, C. D., Shen, Y., Ding, F. H., Yang, Z. K., Hu, J., Shen, W. F., Zhang, R. Y., Lu, L., & Wang, X. Q. (2020) · Figshare · doi:10.6084/m9.figshare.12910553
Lartey, A. H., Li, X., Li, Z., Zhang, Q., & Wang, J. (2021) · Figshare · doi:10.6084/m9.figshare.13843583
Zhang, F., Shi, T., Feng, X., Shi, Y., Zhang, G., Liu, Y., & Fu, P. (2023) · Figshare · doi:10.6084/m9.figshare.24223777
Bi, J., Song, L., Wang, L., Wu, M., Chen, S., Wang, Y., Wu, S., & Tian, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16822753
Pei, J., Wang, X., Pei, Z., & Hu, X. (2023) · Figshare · doi:10.6084/m9.figshare.24452462
Koška, J., Nuyujukian, D. S., Bahn, G., Zhou, J. J., & Reaven, P. D. (2021) · Figshare · doi:10.6084/m9.figshare.17149648
Self-citationWu, C., Hu, X., Tang, L., Wu, Z., Huang, Z., & Fang, C. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05089-6
Sugimoto, H., Hironaka, K., Yamada, T., Otowa‐Suematsu, N., Hirota, Y., Otake, H., Hirata, K., Sakaguchi, K., Ogawa, W., & Kuroda, S. (2026) · eLife · doi:10.7554/elife.102860.2
Oltre i target glicemici: effetto legacy e variabilità glicemica nelle complicanze del diabete
Barone, S., & Sacchetta, L. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01765-7
Smati, S., Boureau, A., Gourdy, P., Guyomarch, B., Annweiller, C., Briet, C., Cervantes, N., de Decker, L., Delabrière, I., Guyonnet, S., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101775
Li, S. J., Nuyujukian, D. S., McClelland, R. L., Reaven, P. D., Zhou, J., Zhou, H., & Li, G. (2026) · The Annals of Applied Statistics · doi:10.1214/26-aoas2218
Self-citation
Metadata
- Authors
- Zhou, J. J., Schwenke, D. C., Bahn, G., & Reaven, P.
- Affiliations
- University of Arizona (US)
- Carl T. Hayden Veterans Affairs Medical Center (US)
- Edward Hines, Jr. VA Hospital (US)
- Corresponding author
- Zhou, Jin J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-08-06
- Volume
- 41
- Issue
- 10
- Pages
- 2187-2194
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6150432
- OpenAlex
- W2887193038
- Cited by
- 131
- References
- 37
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 9 · 2023: 24 · 2022: 16 · 2021: 23 · 2020: 24 · 2019: 17
- FWCI
- 12.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R01-067690, 5R01-094775, K01-DK-106116)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- glycemic variability, cardiovascular disease, type 2 diabetes, fasting blood glucose, HbA1c, tight glycemic control, coefficient of variation, average real variability, hypoglycemia
- MeSH terms
- Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Fasting, Female, Glycated Hemoglobin, Humans, Male, Middle Aged, Risk Factors, Veterans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
